Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
Trending
- Why fall yard care could start with doing less – but not nothing
- Canada Targets People With Dementia for Euthanasia
- Poll Shows Deep Blue State Flipping Red On Hot-Button Issue
- Why identity needs a heartbeat, not a checkpoint
- The ‘Cornell 7’ Lesson: Don’t Do Drugs, Stay In School
- ‘I Don’t Want to Fight Him’ – Donald Trump Brings New Face to Campaign Rally: The Bronx Bull
- DOJ files complaint against 7 Minnesota federal judges over political bias
- Euthanasia by Advanced Request is Euthanasia Without Consent
- JUST IN: Hurricane Isaias Makes Landfall In Florida As Category 2 Storm
- Volkswagen’s replacement for the ID.4 crossover is here